Prevalence_NN of_IN Oxacillin_NP Resistance_NP in_IN Staphylococcus_NP aureus_NN among_IN Inpatients_NNS and_CC Outpatients_NNS in_IN the_DT United_NP States_NPS during_IN 2000_CD acquired_VBN infections_NNS with_IN methicillin-resistant_JJ Staphylococcus_NP aureus_NN (_( MRSA_NP )_) are_VBP cause_NN for_IN concern_NN ._SENT However_RB ,_, not_RB all_DT MRSA_NP infections_NNS detected_VBD within_IN the_DT community_NN were_VBD acquired_VBN there_RB ._SENT In_IN recent_JJ years_NNS ,_, healthcare_NN practices_NNS have_VBP shifted_VBN MRSA-infected_JJ individuals_NNS from_IN hospitals_NNS into_IN surrounding_VBG communities_NNS ,_, for_IN treatment_NN and_CC convalescence_NN at_IN home_NN ,_, for_IN example_NN ._SENT While_IN the_DT epidemiology_NN of_IN nosocomial_JJ MRSA_NP has_VBZ been_VBN well_RB studied_VBN ,_, less_CC is_VBZ known_VBN about_IN the_DT dissemination_NN of_IN MRSA_NP within_IN communities_NNS surrounding_VBG hospitals_NNS ._SENT Generally_RB ,_, apart_RB from_IN unique_JJ community_NN strains_NNS ,_, it_PP has_VBZ been_VBN thought_VBN that_IN MRSA_NP is_VBZ transferred_VBN from_IN hospital_NN environments_NNS ,_, known_VBN reservoirs_NNS of_IN antimicrobial_JJ resistance_NN ,_, into_IN surrounding_VBG communities_NNS ._SENT Additionally_RB ,_, patients_NNS may_MD become_VB carriers_NNS of_IN MRSA_NP during_IN a_DT stay_NN in_IN a_DT healthcare_NN institution_NN and_CC later_RBR ,_, perhaps_RB at_IN home_NN ,_, manifest_VBP an_DT infection_NN from_IN this_DT MRSA_NP ,_, blurring_VBG the_DT definitions_NNS of_IN community-_NN and_CC hospital-acquired_JJ infections_NNS ._SENT If_IN these_DT assumptions_NNS were_VBD true_JJ ,_, one_PP would_MD expect_VB the_DT prevalence_NN of_IN MRSA_NP to_TO be_VB higher_JJR in_IN outpatients_NNS served_VBN by_IN hospitals_NNS with_IN higher_JJR rates_NNS of_IN MRSA_NP ._SENT To_TO test_VB this_DT hypothesis_NN ,_, we_PP analyzed_VBD data_NNS from_IN The_DT Surveillance_NP Network_NP (_( TSN_NP )_) Database_NN --_: -USA_NP (_( Focus_NP Technologies_NP ,_, Inc._NP ,_, Herndon_NP ,_, Va._NP )_) ._SENT TSN_NP Database_NP --_: -USA_NP electronically_RB collects_VBZ daily_JJ routine_JJ antimicrobial_JJ susceptibility_NN testing_NN and_CC patient_JJ demographic_JJ data_NNS from_IN laboratories_NNS ,_, which_WDT are_VBP the_DT data_NNS upon_IN which_WDT clinical_JJ decisions_NNS are_VBP made_VBN ._SENT Participant_NN institutions_NNS are_VBP geographically_RB dispersed_VBN throughout_IN the_DT nine_CD U.S._NP Census_NP Bureau_NP regions_NNS ._SENT All_DT data_NNS are_VBP filtered_VBN through_IN expert_JJ rule_NN algorithms_NNS to_TO remove_VB repeat_NN isolates_NNS and_CC identify_VB microbiologically_RB atypical_JJ results_NNS for_IN confirmation_NN or_CC verification_NN before_IN being_VBG merged_VBN into_IN the_DT final_JJ database_NN ._SENT The_DT information_NN provided_VBD to_TO TSN_NP databases_NNS allows_VBZ us_PP to_TO confidently_RB differentiate_VB inpatients_NNS from_IN outpatients_NNS but_CC does_VBZ not_RB allow_VB us_PP to_TO determine_VB whether_IN an_DT infection_NN was_VBD community_NN or_CC hospital_NN acquired_VBD ._SENT Outpatient_NN data_NNS contained_VBN in_IN TSN_NP databases_NNS also_RB include_VBP isolates_NNS from_IN emergency_NN room_NN visits_NNS ._SENT For_IN this_DT analysis_NN ,_, we_PP excluded_VBD isolates_NNS from_IN nursing_VBG home_NN and_CC other_JJ long-term-care-facility_NN patients_NNS ,_, frequently_RB colonized_VBN with_IN MRSA_NP ._SENT To_TO test_VB our_PP$ hypothesis_NN that_IN a_DT relationship_NN exists_VBZ between_IN the_DT prevalence_NN of_IN MRSA_NP in_IN outpatients_NNS and_CC inpatients_NNS in_IN the_DT same_JJ geographic_JJ area_NN ,_, we_PP reviewed_VBD routine_JJ laboratory_NN data_NNS comprising_VBG 264,687_CD nonrepeat_JJ isolates_NNS of_IN S._NP aureus_NN collected_VBN in_IN 2000_CD from_IN 121_CD hospitals_NNS in_IN TSN_NP Database_NP --_: -USA_NP ,_, each_DT testing_NN at_IN least_JJS 100_CD isolates_NNS ._SENT A_DT highly_RB significant_JJ relationship_NN (_( P_NN <_SYM 0.0001_CD )_) was_VBD found_VBN between_IN the_DT rates_NNS of_IN MRSA_NP among_IN outpatient_NN and_CC inpatient_NN isolates_NNS of_IN S._NP aureus_NN in_IN 2000_CD ._SENT This_DT relationship_NN was_VBD confirmed_VBN by_IN linear_JJ regression_NN analysis_NN (_( r_LS =_SYM 0.75_CD )_) ._SENT Almost_RB invariably_RB ,_, hospitals_NNS with_IN higher_JJR rates_NNS of_IN MRSA_NP among_IN their_PP$ inpatients_NNS had_VBD higher_JJR rates_NNS of_IN MRSA_NP among_IN outpatient_NN isolates_NNS submitted_VBN to_TO their_PP$ laboratories_NNS for_IN culture_NN and_CC antimicrobial_JJ susceptibility_NN testing_NN ._SENT Similarly_RB ,_, hospitals_NNS with_IN lower_JJR rates_NNS of_IN MRSA_NP among_IN their_PP$ inpatients_NNS had_VBD lower_JJR rates_NNS of_IN MRSA_NP among_IN outpatients_NNS from_IN their_PP$ surrounding_VBG communities_NNS ._SENT Multiple_JJ drug_NN resistance_NN ,_, defined_VBN as_IN concurrent_JJ resistance_NN to_TO three_CD or_CC more_JJR antimicrobial_JJ drug_NN classes_NNS ,_, comprised_VBD 76.1_CD %_NN and_CC 66.5_CD %_NN of_IN inpatient_NN and_CC outpatient_NN isolates_NNS ,_, respectively_RB ._SENT The_DT prevalence_NN of_IN MRSA_NP has_VBZ continued_VBN to_TO increase_VB in_IN the_DT United_NP States_NPS ._SENT A_DT retrospective_JJ analysis_NN of_IN TSN_NP Database_NP --_: -USA_NP showed_VBD that_IN the_DT prevalence_NN of_IN MRSA_NP in_IN 33_CD hospitals_NNS participating_VBG from_IN 1996_CD to_TO 2000_CD increased_VBN from_IN 30.1_CD %_NN (_( 4,557/15,143_CD )_) in_IN 1996_CD to_TO 45.7_CD %_NN (_( 27,495/60,149_CD )_) in_IN 2000_CD (_( P_NN <_SYM 0.0001_CD )_) in_IN inpatient_NN isolates_NNS ;_: among_IN outpatient_NN isolates_NNS ,_, the_DT prevalence_NN of_IN MRSA_NP increased_VBD from_IN 17.3_CD %_NN (_( 1,781/10,268_CD )_) to_TO 28.6_CD %_NN (_( 17,858/62,401_CD )_) (_( P_NN <_SYM 0.0001_CD )_) ._SENT Previous_JJ reports_NNS have_VBP noted_VBN a_DT growing_VBG concern_NN regarding_VBG MRSA_NP infections_NNS within_IN some_DT community_NN populations_NNS ,_, particularly_RB in_IN children_NNS and_CC those_DT with_IN dermatological_JJ disorders_NNS ,_, renal_JJ dysfunction_NN ,_, or_CC HIV_NP infection_NN ._SENT The_DT clear_JJ relationship_NN between_IN the_DT rates_NNS of_IN MRSA_NP infection_NN among_IN inpatients_NNS and_CC outpatients_NNS demonstrated_VBD here_RB illustrates_VBZ that_IN MRSA_NP infections_NNS are_VBP no_RB longer_RBR confined_VBN to_TO hospitals_NNS and_CC are_VBP certainly_RB present_JJ in_IN the_DT community_NN ._SENT It_PP is_VBZ likely_JJ that_IN these_DT include_VBP both_DT distinct_JJ community_NN clones_NNS and_CC those_DT carried_VBN by_IN patients_NNS formerly_RB either_CC directly_RB or_CC indirectly_RB exposed_VBN to_TO the_DT healthcare_NN environment_NN ,_, as_RB demonstrated_VBN in_IN a_DT recent_JJ U.S._NP study_NN ._SENT The_DT present_JJ report_NN corroborates_VBZ the_DT need_NN for_IN heightened_JJ awareness_NN of_IN MRSA_NP among_IN community_NN health-care_NN practitioners_NNS ,_, including_VBG up-to-date_JJ knowledge_NN of_IN trends_NNS in_IN MRSA_NP at_IN local_JJ and_CC regional_JJ levels_NNS ._SENT There_EX is_VBZ also_RB a_DT need_NN for_IN more_RBR rapid_JJ ,_, reliable_JJ methods_NNS to_TO detect_VB and_CC report_VB the_DT presence_NN of_IN methicillin_NN resistance_NN among_IN isolates_NNS of_IN S._NP aureus_NN ,_, especially_RB among_IN outpatients_NNS ,_, as_IN standard_JJ empirical_JJ therapies_NNS may_MD not_RB be_VB effective_JJ in_IN treating_VBG infections_NNS by_IN MRSA_NP ,_, especially_RB those_DT derived_VBN from_IN hospital_NN environments_NNS with_IN a_DT greater_JJR tendency_NN for_IN multidrug_NN resistance_NN ._SENT FIG._NN 1_CD ._SENT :_: The_DT proportion_NN of_IN MRSA_NP in_IN outpatient_NN samples_NNS plotted_VBD against_IN the_DT proportion_NN of_IN MRSA_NP in_IN inpatient_NN samples_NNS for_IN each_DT of_IN the_DT 121_CD hospitals_NNS able_JJ to_TO be_VB evaluated_VBN which_WDT participated_VBD in_IN TSN_NP Database_NP --_: -USA_NN during_IN 2000_CD ._SENT The_DT proportion_NN of_IN MRSA_NP in_IN outpatient_NN samples_NNS plotted_VBD against_IN the_DT proportion_NN of_IN MRSA_NP in_IN inpatient_NN samples_NNS for_IN each_DT of_IN the_DT 121_CD hospitals_NNS able_JJ to_TO be_VB evaluated_VBN which_WDT participated_VBD in_IN TSN_NP Database_NP --_: -USA_NN during_IN 2000_CD ._SENT 